TBA (17A117)

Baricitinib Inhibits Radiographic Progression of Structural Joint Damage at 1 Year in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to csDMARDs

Author(s)

Erica Tierney (non-author presenter)1, Désirée van der Heijde2, Maxime Dougados3, Ying-Chou Chen4, Maria Greenwald5, Edit Drescher6, Rena Klar7, Li Xie8, Inmaculada de la Torre8, Terence Rooney8, Sarah Witt8, Douglas Schlichting8, Stephanie de Bono8, Paul Emery9

Department(s)/Institutions

1Eli Lilly and Company Limited, Lilly Ireland, Dublin, Ireland; 2Leiden University Medical Center, Leiden, The Netherlands; 3Department of Rheumatology, Cochin Hospital, Paris, France; 4Chang Gung Memorial Hospital, Kaohsiung, Taiwan; 5Desert Medical Advances, Palm Desert, USA; 6Veszprém Csolnoky Ferenc County Hospital, Vészprem, Hungary; 7Quintiles Transnational INC, Durham, USA; 8Eli Lilly & Company, Indianapolis, USA; 9Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

Introduction

Baricitinib (bari), a JAK1/2 inhibitor, was efficacious in a 24-week (wk) Ph 3 study in patients (pts) with active RA and an inadequate response (IR) to conventional synthetic DMARDs (csDMARDs) (RA-BUILD).

Aims/Background

To evaluate radiographic progression of structural joint damage in RA-BUILD pts with IR or intolerance to ≥1 csDMARD over 48 wks of bari treatment in the long-term extension study, RA-BEYOND.

Method

In the 24-wk RA-BUILD study, pts were randomized to placebo (PBO) (N=228), bari 2mg (N=229) or bari 4mg (N=227) once daily (QD), with rescue possible from Wk16. Pts completing RA-BUILD and entering RA-BEYOND continued to receive the bari dose received at the end of RA-BUILD. Pts receiving PBO at the end of RA-BUILD were switched to bari 4mg in RA-BEYOND. Pt and investigator blinding was maintained in RA-BEYOND. Joint damage was measured using the van der Heijde modified total Sharp score (mTSS). To account for missing scores and scores obtained after rescue or discontinuation of study drug, data were analyzed using 1) linear extrapolation (LE), and 2) last observation carried forward (LOCF). The observed/LOCF method used all available observed data, including after rescue or switch, with pts analyzed according to original treatment assignment.

Results

Using LE, progression of mTSS, bone erosion, and joint space narrowing (JSN) at 24 and 48 wks was statistically significantly lower for both bari 2 or 4mg compared to PBO (p≤0.05). Only bari 4mg demonstrated statistically significant inhibition of progressive radiographic joint damage compared to PBO using observed/LOCF at Wk 48 or based on categorical measures (p≤0.05).

Conclusions

Once daily oral bari inhibited radiographic progression of structural joint damage in pts with an IR or intolerance to csDMARDs over 48 wks of treatment. The most robust benefit across measures of radiographic progression was seen for the 4mg dose.

This abstract was previously presented at EULAR 2016 London, UK 8-11 June and published in the Annals of the Rheumatic Diseases, June 2016, Volume 75 (Supplement 2), pages 244-245.